Company CEO Gary Delanois said that the company is “rapidly evolving” from its traditional leasing model to a direct provider of radiation therapy treatment services to cancer patients.
Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.
The seat belt pretensioner in the vehicles may inadvertently lock the belt, not allowing it to retract or extend, and increasing the risk of injury in case of crash.
The brokerage highlighted that since its public listing in April 2024, the company has mostly exceeded consensus expectations and continued executing its organic and inorganic growth strategy.
Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall Street Journal reported.
Truist Securities noted that the numbers aligned with the company’s prior commentary and street estimates, although the shares could see headwinds today from Tesla reporting Q1 deliveries below estimates before market open.
Deliveries of the company’s mass-market offerings- the Model 3 and Model Y- fell by 12.4%, while those of its three more premium offerings collectively fell by about 24%.
The medical technology company now expects net sales to be $285 to $288 million for the fiscal year 2025, up from previously issued guidance of $282 to $288 million, owing to increased medical technology net sales.
Roblox said the partnership with Google is a foundational element in its advertising vision, enabling it to quickly scale its Rewarded Video ads and other immersive ads offerings.
CoreWeave’s IPO was marred by weak stock market conditions and the uncertain economic outlook, which forced the company to downsize the size of the public offering to 37.5 million shares from the initially planned 49 million.
Red Cat recorded a net loss of $0.57 per share on $4.9 million in revenue for the final eight months of 2024, with 2025 revenue guidance of $80 million to $120 million.
